ERBB2 and breast carcinoma: Response to therapy allows for a possible de-escalation of surgical intervention in the axilla and constitutes an important predictive factor for adjuvant treatment escalation according to breast cancer molecular subtypes defined by hormonal receptor status and HER2 overexpression.